Kidney Week

Abstract: SA-PO016

Real-World Data in an Observational Medical Outcomes Partnership/Common Data Model (OMOP/CDM) Platform: Assessing the Impact of Statins on Reducing the Need for Dialysis of Diabetic Patients Treated with ARBs/ACE Inhibitors

Session Information

• Augmented Intelligence, Large Language Models, and Digital Health
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Augmented Intelligence, Digital Health, and Data Science

• 300 Augmented Intelligence, Digital Health, and Data Science

Authors

• Truyts, Cesar Augusto madid, Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Cesar Augusto madid Truyts, MD, MSc, MBA

• Passos, Rogerio, Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Rogerio Passos, MD

• Abrahao, Maria Tereza Fernandes, Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Maria Tereza Fernandes Abrahao, PhD

• Flato, Uri Prync, Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Uri Prync Flato, MD

• Rabelo, Amanda G., Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Amanda G. Rabelo

• Freitas, Mateus de Lima, Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Mateus de Lima Freitas, MD, MBA

• Patrão, Diogo Fc, Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Diogo Fc Patrão, PhD

• Amaro Junior, Edson, Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Edson Amaro Junior, MD, PhD

• Pereira, Adriano José, Sociedade Beneficente Israelita Brasileira Albert Einstein, Sao Paulo, São Paulo, Brazil

Adriano José Pereira, MD, PhD

Background

Diabetics are at high risk of developing kidney dysfunction. Angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) are often employed to mitigate the risk of kidney disease progression. Statins also show promise in reducing the risk of chronic kidney disease (CKD) progression. This study examines the impact of statins on reducing the need for dialysis among diabetic patients treated with ACEIs or ARBs, utilizing the OMOP CDM framework within the Hospital Israelita Albert Einstein in São Paulo/Brazil.

Methods

This retrospective, observational cohort study at a single hospital used the OMOP CDM framework to analyze electronic health records of diabetic patients treated with ACEIs/ARBs, from 2017 to 2023. Adult Type 2 Diabetes Mellitus patients receiving ACEIs/ARBs, and possibly statins were included. Statistical analyses using Python involved Chi-square and Mann-Whitney U tests, and multivariate logistic regression, ensuring significance with p-values less than 0.05.

Results

Out of 55,764 diabetic patients using ACEIs or ARBs, 36,378 (65.2%) were taking statins. Statin users were older (median [range], 65 years [53–75] vs. 45 years [35–59]; P < 0.01) and predominantly male (56% vs. 44%; P < 0.001). Logistic regression adjusted for age and sex showed that statin users had a lower dialysis rate (0.20% vs. 2.88%; P < 0.001 - Table 1)

Conclusion

The data suggest that statin therapy was associated with a reduced need for dialysis in high-risk diabetic patients with ACEIs/ARBs. The OMOP CDM framework was an easy way to simplify and accelerate analysis of large amount of data, in an integrated and protected environment, highlighting its value in advanced medical research.

Baseline demographics